Novo Nordisk’s Wegovy and copyright, both equally powered by semaglutide, have revolutionized obesity treatment by way of unprecedented weight loss effects.This led Novo Nordisk to carry out additional study into increased dosages of semaglutide specifically for weight administration.By 2022 the popularity of Novo's Wegovy and copyright for weigh